Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06422143 · ClinicalTrials.gov registry record · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
A Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 851
- Enrollment target
- 20
- Study locations
NCT06422143: Recruiting Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Merck Sharp & Dohme.
NCT06422143 is a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 851 participants, above the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06422143, a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 851 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).
Primary Outcome
OS is the time from randomization to death due to any cause.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
- BIOLOGICAL sac-TMT
Study Locations (20)
Georgia
- Centricity Research Columbus Cancer Center ( Site 0111) - Columbus
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001) - Marietta
- Southeastern Regional Medical Center ( Site 0004) - Newnan
Texas
- Memorial Hermann Cancer Center ( Site 0015) - Houston
- Oncology Consultants P.A. ( Site 0124) - Houston
- Mays Cancer Center ( Site 0132) - San Antonio
Colorado
- Exempla Lutheran Medical Center ( Site 0119) - Golden
- Intermountain Health St. Mary's Regional Hospital ( Site 0116) - Grand Junction
New Mexico
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0123) - Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0135) - Albuquerque
Pennsylvania
- St Luke's University Health Network ( Site 0017) - Bethlehem
- Thomas Jefferson University - Clinical Research Institute ( Site 0147) - Philadelphia
Buenos Aires
- Instituto Alexander Fleming ( Site 0203) - Ciudad Autónoma de Buenos Aires
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0200) - Mar del Plata
Arkansas
- CARTI Cancer Center ( Site 0006) - Little Rock
California
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122) - Burbank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2031-02-12 |
| Phase | Phase 3 |
What NCT06422143 shows while recruiting
NCT06422143 is an interventional study that assigns participants to a tested intervention. The registered 851 participants enrollment target is mid-sized for trials with a published cap, above the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (31% higher).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06422143 names 20 study sites across 12 states, led by Georgia, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT06422143 about?
NCT06422143 is a clinical study titled "Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]". This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesize...
What is the current status of trial NCT06422143?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 851 participants. The study started on 2024-06-10. Estimated completion is 2031-02-12.
What conditions does trial NCT06422143 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC.
What interventions are being tested in trial NCT06422143?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG), sac-TMT (BIOLOGICAL).
Who is sponsoring clinical trial NCT06422143?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06422143 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06422143's enrollment target sits among peer trials
851 32nd of 454 higher than 423 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI